April 1, 2019 08:21 AM EDT

AACR: Bay Area biotech bets on antibodies armed with immuno-stimulant to fight checkpoint-resistant cancers

Natalie Grover

Reporter

The scientist behind the first prostate cancer vaccine Provenge — once celebrated as a historic breakthrough, but now a fading star — has devised a type …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AACR: Bay Area biotech bets on antibodies armed with immuno-stimulant to fight checkpoint-resistant cancers

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

From weeks to days: how Aizon Intelligent Agents transform pharma validation

AACR: Bay Area biotech bets on an­ti­bod­ies armed with im­muno-stim­u­lant to fight check­point-re­sis­tant can­cers

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AACR: Bay Area biotech bets on antibodies armed with immuno-stimulant to fight checkpoint-resistant cancers